Key result
IV sodium-channel blockers to unmask Brugada ECG patterns present distinct population-specific benefits and drawbacks.
Why the study?
Because a positive sodium-channel blocker challenge has implications beyond diagnosis, it is necessary to question who should and should not undergo testing to diagnose or exclude Brugada syndrome.
Who should undergo a sodium-channel-blocker test to diagnose or exclude Brugada syndrome?
Who should undergo a sodium-channel-blocker test to diagnose or exclude Brugada syndrome?
This review provides guidance on the appropriate selection of patients for sodium-channel-blocker testing to diagnose Brugada syndrome.
No takes yet. Share an insight, caveat, or question.
May inform patient selection for Brugada unmasking tests; leaves open need for prospective validation of criteria.
Viskin et al. (2024) conducted a review in Brugada syndrome. Sodium-channel blockers (ajmaline, flecainide, procainamide, or pilsicainide) was evaluated. Intravenous infusion of sodium-channel blockers to unmask Brugada syndrome ECG patterns presents specific benefits and drawbacks across different patient populations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: